Literature DB >> 3204255

Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.

J Bousquet1, A Hejjaoui, A M Clauzel, B Guérin, H Dhivert, W Skassa-Brociek, F B Michel.   

Abstract

House dust mites of the species Dermatophagoides pteronyssinus (Dpt) represent one of the major allergens inducing asthma. However, a strict allergy to Dpt is not always observed in Dpt-allergic patients, since nonallergic and other allergic triggering factors often coexist. It was suggested that specific immunotherapy with house dust-mite extracts is more effective in children than in adults. A controlled study was undertaken in 215 Dpt-allergic patients with asthma ranging in age from 3 to 72 years (mean +/- SD, 28.2 +/- 10.9 years) to investigate parameters that might predict the efficacy of specific immunotherapy before it is started; 171 patients received a rush immunotherapy protocol with a standardized Dpt extract and, subsequently, maintenance injections with 3000 BU of this extract, and 44 patients served as a control group. Before immunotherapy, all patients had a complete evaluation of the severity of asthma by symptom-medication scores and a pulmonary function test, as well as a study of other triggering factors by checking on seasonal and perennial allergens, sinusitis, and other possible causes, such as aspirin intolerance; 196 patients were investigated between 9 and 12 months after the onset of the survey by means of pulmonary function tests and symptom-medication scores. Medications were adapted according to peak flow rates. It was observed that patients with chronic sinusitis, and/or aspirin intolerance, and/or other perennial allergies did not benefit from specific immunotherapy; therefore, the treatment of a major etiologic factor did not demonstrate improvement in the patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3204255     DOI: 10.1016/0091-6749(88)90133-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

1.  Desensitisation today.

Authors: 
Journal:  BMJ       Date:  1990-08-04

Review 2.  Immunotherapy in asthma.

Authors:  J A Douglass; F C Thien; R E O'Hehir
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 3.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 4.  Specific immunotherapy in house dust mite allergy.

Authors:  J Bousquet; A Des Roches; L Paradis; H Dhivert; F B Michel
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 5.  Minimising the risks of allergen-specific injection immunotherapy.

Authors:  H J Malling
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

6.  Effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real-life prospective observational study.

Authors:  Clara Padró; Diego Gutiérrez; Francisco Moreno; Antonio Parra; Manuel J Rial; Ramón Lleonart; Carla Torán-Barona; José L Justicia; Albert Roger
Journal:  Immun Inflamm Dis       Date:  2022-05

7.  The inverse association between the presence of antibody to hepatitis B surface antigen and atopy in young adults.

Authors:  Youngil I Koh; Inseon S Choi; Chang-Hwan Park; Jae-Sook Ahn; Seung-Gyu Ji
Journal:  Korean J Intern Med       Date:  2005-09       Impact factor: 2.884

Review 8.  Asthma in children and adolescents: a comprehensive approach to diagnosis and management.

Authors:  Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

Review 9.  Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews.

Authors:  Felix Asamoah; Artemisia Kakourou; Sangeeta Dhami; Susanne Lau; Ioana Agache; Antonella Muraro; Graham Roberts; Cezmi Akdis; Matteo Bonini; Ozlem Cavkaytar; Breda Flood; Kenji Izuhara; Marek Jutel; Ömer Kalayci; Oliver Pfaar; Aziz Sheikh
Journal:  Clin Transl Allergy       Date:  2017-08-02       Impact factor: 5.871

10.  Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients.

Authors:  Letícia Sousa; Carmen Martín-Sierra; Celso Pereira; Graça Loureiro; Beatriz Tavares; Susana Pedreiro; António Martinho; Artur Paiva
Journal:  Allergy Asthma Clin Immunol       Date:  2018-11-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.